REGEN 2013: Clinical Trials & Reimbursement
19 Mar 2013 - 21 Mar 2013 - Boston, MA, USA
The potential for regenerative medicine is obvious. But the route to market is not.
With only a small number of approved regenerative therapies on the market and many clinical trials currently being completed on a small scale, the opportunities to learn from completed clinical trials are slim. With complex processing and confusion surrounding expectations from regulators and investors, the regenerative medicine field is facing huge uncertainty on how best to proceed through the clinic with these pioneering products.
REGEN 2013 is the only meeting which will explore the pioneering clinical trials in the field to enable you to learn from their successes and failures and adopt industry best practice.
Understand the clinical strategies for some of the most promising regenerative medicines to enable you to optimise your practices and push your therapy through to patients faster.
Designed to give you access to the acquired knowledge and experience of the industry, REGEN 2013 will provide a unique opportunity for you to identify common flaws in clinical trial designs in order to design the most effective clinical strategy for your product.